ID   OCI-Ly7
AC   CVCL_1881
SY   OCI-LY7; OCI-LY-7; OCI-Ly-7; Oci-Ly-7; OCI-Ly 7; OCI-Ly07; OCILY7; Ly7; LY7
DR   BTO; BTO:0006414
DR   EFO; EFO_0006711
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 1398
DR   BioSample; SAMN03473439
DR   cancercelllines; CVCL_1881
DR   Cell_Model_Passport; SIDM00459
DR   ChEMBL-Cells; CHEMBL4523533
DR   ChEMBL-Targets; CHEMBL4523564
DR   Cosmic; 1329092
DR   Cosmic; 1517649
DR   Cosmic; 1541903
DR   Cosmic; 1629934
DR   Cosmic; 1945199
DR   Cosmic; 2276331
DR   Cosmic-CLP; 1659819
DR   DepMap; ACH-001617
DR   DSMZ; ACC-688
DR   DSMZCellDive; ACC-688
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   ENCODE; ENCBS006VZG
DR   ENCODE; ENCBS040MJM
DR   ENCODE; ENCBS062JSC
DR   ENCODE; ENCBS121JKZ
DR   ENCODE; ENCBS141AMI
DR   ENCODE; ENCBS182NFY
DR   ENCODE; ENCBS304FAI
DR   ENCODE; ENCBS581USS
DR   ENCODE; ENCBS699NWP
DR   ENCODE; ENCBS865AAA
DR   ENCODE; ENCBS866AAA
DR   ENCODE; ENCBS886BJZ
DR   GDSC; 1659819
DR   GEO; GSM380135
DR   GEO; GSM552453
DR   GEO; GSM562825
DR   GEO; GSM1035333
DR   GEO; GSM1059809
DR   GEO; GSM1374789
DR   PharmacoDB; OCILY7_1187_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_1881
DR   PubChem_Cell_line; CVCL_1881
DR   Wikidata; Q54931777
RX   PubMed=3567358;
RX   PubMed=8574164;
RX   PubMed=11807979;
RX   PubMed=15126345;
RX   PubMed=19278952;
RX   PubMed=19358282;
RX   PubMed=20054396;
RX   PubMed=20628145;
RX   PubMed=23257783;
RX   PubMed=23292937;
RX   PubMed=23699601;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=27397505;
RX   PubMed=27566572;
RX   PubMed=28196595;
RX   PubMed=30894373;
RX   PubMed=31160637;
RX   PubMed=35839778;
WW   http://www.innovationbridge.com/uhn/diffuse-large-b-cell-lymphoma-cell-lines?categories=32&communities=5&forums=&organizations=&tags=
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Ontario Cancer Institute (OCI); Toronto; Canada.
CC   Population: Caucasian.
CC   Characteristics: Genetically heterogeneous, consists of 2 subclones (PubMed=27566572).
CC   Doubling time: ~20-24 hours (DSMZ=ACC-688).
CC   HLA typing: A*01:01; B*13; C*04:01; DQA1*05:02,05:02; DQB1*03:09,03:09; DRB1*13:03,07:01 (PubMed=25960936).
CC   HLA typing: A*01:01:01,01:01:01; B*35:02:01,35:02:01; C*04:01:01,04:01:01; DPA1*01:03:01,01:03:01; DPB1*03:01:01,17:01; DQA1*05:05:01,05:05:01; DQB1*03:01:01,03:01:01; DRA*01:02:02,01:02:02; DRB1*13:03:01,13:03:01 (DSMZCellDive=ACC-688).
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Sequence variation: Gene fusion; HGNC; 5477; IGH + HGNC; 7553; MYC; Name(s)=MYC-IGH (PubMed=31160637; DSMZ=ACC-688).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: H3K9ac ChIP-seq epigenome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=0.44%; Native American=0.13%; East Asian, North=0%; East Asian, South=0.31%; South Asian=1.19%; European, North=69.58%; European, South=28.35% (PubMed=30894373).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): Cosmic-CLP; DepMap; DSMZ
ST   Amelogenin: X,Y
ST   CSF1PO: 12,13
ST   D13S317: 11,12
ST   D16S539: 12,13
ST   D18S51: 20
ST   D19S433: 14,16
ST   D21S11: 29,31.2
ST   D2S1338: 22,24
ST   D3S1358: 14,17
ST   D5S818: 11,12
ST   D7S820: 10
ST   D8S1179: 13,15
ST   FGA: 20
ST   Penta D: 11,13
ST   Penta E: 11,12
ST   TH01: 6,9.3
ST   TPOX: 8,12
ST   vWA: 15,18
DI   NCIt; C36080; Diffuse large B-cell lymphoma germinal center B-cell type
DI   ORDO; Orphanet_544; Diffuse large B-cell lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   48Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 40
//
RX   PubMed=3567358; DOI=10.1182/blood.V69.5.1307.1307;
RA   Tweeddale M.E., Lim B., Jamal N., Robinson J., Zalcberg J.R.,
RA   Lockwood G., Minden M.D., Messner H.A.;
RT   "The presence of clonogenic cells in high-grade malignant lymphoma: a
RT   prognostic factor.";
RL   Blood 69:1307-1314(1987).
//
RX   PubMed=8574164; DOI=10.3109/10428199509059672;
RA   Chang H., Blondal J.A., Benchimol S., Minden M.D., Messner H.A.;
RT   "p53 mutations, c-myc and bcl-2 rearrangements in human non-Hodgkin's
RT   lymphoma cell lines.";
RL   Leuk. Lymphoma 19:165-171(1995).
//
RX   PubMed=11807979; DOI=10.1002/gcc.10025;
RA   Mehra S., Messner H.A., Minden M.D., Chaganti R.S.K.;
RT   "Molecular cytogenetic characterization of non-Hodgkin lymphoma cell
RT   lines.";
RL   Genes Chromosomes Cancer 33:225-234(2002).
//
RX   PubMed=15126345; DOI=10.1158/0008-5472.CAN-03-3773;
RA   Ota A., Tagawa H., Karnan S., Tsuzuki S., Karpas A., Kira S.,
RA   Yoshida Y., Seto M.;
RT   "Identification and characterization of a novel gene, C13orf25, as a
RT   target for 13q31-q32 amplification in malignant lymphoma.";
RL   Cancer Res. 64:3087-3095(2004).
//
RX   PubMed=19278952; DOI=10.1182/blood-2009-01-202028;
RA   Li C., Kim S.-W., Rai D., Bolla A.R., Adhvaryu S., Kinney M.C.,
RA   Robetorye R.S., Aguiar R.C.T.;
RT   "Copy number abnormalities, MYC activity, and the genetic fingerprint
RT   of normal B cells mechanistically define the microRNA profile of
RT   diffuse large B-cell lymphoma.";
RL   Blood 113:6681-6690(2009).
//
RX   PubMed=19358282; DOI=10.1002/ijc.24351;
RA   Inagaki A., Ishida T., Yano H., Ishii T., Kusumoto S., Ito A., Ri M.,
RA   Mori F., Ding J.-M., Komatsu H., Iida S., Ueda R.;
RT   "Expression of the ULBP ligands for NKG2D by B-NHL cells plays an
RT   important role in determining their susceptibility to
RT   rituximab-induced ADCC.";
RL   Int. J. Cancer 125:212-221(2009).
//
RX   PubMed=20054396; DOI=10.1038/nature08638;
RA   Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B.,
RA   Kohlhammer H., Lamy L., Zhao H., Yang Y.-D., Xu W.-H., Shaffer A.L. III,
RA   Wright G., Xiao W.-M., Powell J.I., Jiang J.-K., Thomas C.J., Rosenwald A.,
RA   Ott G., Muller-Hermelink H.-K., Gascoyne R.D., Connors J.M.,
RA   Johnson N.A., Rimsza L.M., Campo E., Jaffe E.S., Wilson W.H.,
RA   Delabie J., Smeland E.B., Fisher R.I., Braziel R.M., Tubbs R.R.,
RA   Cook J.R., Weisenburger D.D., Chan W.C., Pierce S.K., Staudt L.M.;
RT   "Chronic active B-cell-receptor signalling in diffuse large B-cell
RT   lymphoma.";
RL   Nature 463:88-92(2010).
//
RX   PubMed=20628145; DOI=10.1182/blood-2010-05-282780;
RA   Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T.,
RA   O'Donnell E., Chapuy B., Takeyama K., Neuberg D., Golub T.R.,
RA   Kutok J.L., Shipp M.A.;
RT   "Integrative analysis reveals selective 9p24.1 amplification,
RT   increased PD-1 ligand expression, and further induction via JAK2 in
RT   nodular sclerosing Hodgkin lymphoma and primary mediastinal large
RT   B-cell lymphoma.";
RL   Blood 116:3268-3277(2010).
//
RX   PubMed=23257783; DOI=10.1038/leu.2012.367;
RA   Wenzel S.-S., Grau M., Mavis C., Hailfinger S., Wolf A., Madle H.,
RA   Deeb G., Dorken B., Thome M., Lenz P., Dirnhofer S.,
RA   Hernandez-Ilizaliturri F.J., Tzankov A., Lenz G.;
RT   "MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma.";
RL   Leukemia 27:1381-1390(2013).
//
RX   PubMed=23292937; DOI=10.1073/pnas.1205299110;
RA   Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L.,
RA   Mieczkowski P.A., Dunphy C., Choi W., Au W.Y., Srivastava G.,
RA   Lugar P.L., Rizzieri D.A., Lagoo A.S., Bernal-Mizrachi L., Mann K.P.,
RA   Flowers C.R., Naresh K., Evens A.M., Gordon L.I., Czader M.B., Gill J.I.,
RA   Hsi E.D., Liu Q.-Q., Fan A., Walsh K., Jima D., Smith L.L., Johnson A.J.,
RA   Byrd J.C., Luftig M.A., Ni T., Zhu J., Chadburn A., Levy S.,
RA   Dunson D.B., Dave S.S.;
RT   "Genetic heterogeneity of diffuse large B-cell lymphoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:1398-1403(2013).
//
RX   PubMed=23699601; DOI=10.1182/blood-2013-02-483727;
RA   Morin R.D., Mungall K., Pleasance E.D., Mungall A.J., Goya R.,
RA   Huff R.D., Scott D.W., Ding J.-R., Roth A., Chiu R., Corbett R.D.,
RA   Chan F.C., Mendez-Lago M., Trinh D.L., Bolger-Munro M., Taylor G.,
RA   Hadj Khodabakhshi A., Ben-Neriah S., Pon J., Meissner B., Woolcock B.,
RA   Farnoud N., Rogic S., Lim E.L., Johnson N.A., Shah S., Jones S.J.M.,
RA   Steidl C., Holt R.A., Birol I., Moore R., Connors J.M., Gascoyne R.D.,
RA   Marra M.A.;
RT   "Mutational and structural analysis of diffuse large B-cell lymphoma
RT   using whole-genome sequencing.";
RL   Blood 122:1256-1265(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27566572; DOI=10.18632/oncotarget.11524;
RA   Quentmeier H., Pommerenke C., Ammerpohl O., Geffers R., Hauer V.,
RA   MacLeod R.A.F., Nagel S., Romani J., Rosati E., Rosen A., Uphoff C.C.,
RA   Zaborski M., Drexler H.G.;
RT   "Subclones in B-lymphoma cell lines: isogenic models for the study of
RT   gene regulation.";
RL   Oncotarget 7:63456-63465(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//